2. Search Result
Search Result
Results for "

FGFR-IN-4

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

2

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-10981
    Lenvatinib
    Maximum Cited Publications
    39 Publications Verification

    E7080

    		 VEGFR FGFR PDGFR c-Kit RET Cancer
    Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
    Lenvatinib
  • HY-10981A
    Lenvatinib mesylate
    Maximum Cited Publications
    39 Publications Verification

    E7080 mesylate

    		 VEGFR FGFR PDGFR RET c-Kit Cancer
    Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
    Lenvatinib mesylate
  • HY-19981
    Derazantinib
    1 Publications Verification

    ARQ-087

    		 FGFR Cancer
    Derazantinib (ARQ-087) is an ATP competitive and orally activeFGFR inhibitor (IC50s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3 nM). Derazantinib inhibits FGFR phosphorylation. Derazantinib inhibits tumor growth in multiple xenograft models .
    Derazantinib
  • HY-147619
    FGFR-IN-4

    		FGFR Cancer
    FGFR-IN-4 is a potent inhibitor of FGFR. Fibroblast growth factor receptor (FGFR) is a tyrosine kinase receptor that binds to fibroblast growth factor ligands. FGFR-IN-4 has the potential for the research of cancer diseases (extracted from patent WO2022033532A1, compound 20) . FGFR-IN-4 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    <em>FGFR-IN-4</em>
  • HY-156704
    FGFR4-IN-16

    		FGFR Cancer
    FGFR4-IN-16 (CY-15-2) is a covalent inhibitor of FGFR-4 for cancer research .
    <em>FGFR</em><em>4</em>-IN-16
  • HY-19981B
    Derazantinib dihydrochloride

    ARQ-087 dihydrochloride

    		 EGFR Cancer
    Derazantinib (ARQ-087) dihydrochloride is an ATP competitive and orally activeFGFR inhibitor (IC50s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3). Derazantinib dihydrochloride inhibits FGFR phosphorylation. Derazantinib dihydrochloride inhibits tumor growth in multiple xenograft models .
    Derazantinib dihydrochloride
  • HY-10981S1
    Lenvatinib-d5

    E7080-d5

    		 VEGFR FGFR PDGFR c-Kit RET Cancer
    Lenvatinib-d5 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].
    Lenvatinib-d5
  • HY-10981S
    Lenvatinib-d4

    E7080-d4

    		 VEGFR FGFR PDGFR c-Kit RET Cancer
    Lenvatinib-d4 is the deuterium labeled Lenvatinib. Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities[1][2].
    Lenvatinib-d<em>4</em>
  • HY-133980
    O-Demethyl Lenvatinib

    		Drug Metabolite Cancer
    O-Demethyl Lenvatinib is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, shows potent antitumor activities .
    O-Demethyl Lenvatinib
  • HY-133980A
    O-Demethyl Lenvatinib hydrochloride

    		Drug Metabolite Cancer
    O-Demethyl Lenvatinib hydrochloride is a metabolite of Lenvatinib (HY-10981). Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET. Lenvatinib shows potent antitumor activities .
    O-Demethyl Lenvatinib hydrochloride
  • HY-101768
    PRN1371
    1 Publications Verification

    		 FGFR c-Fms Cancer
    PRN1371 is a highly selective and potent FGFR1-4 and CSF1R inhibitor with IC50s of 0.6, 1.3, 4.1, 19.3 and 8.1 nM for FGFR1, FGFR2, FGFR3, FGFR4 and CSF1R, respectively .
    PRN1371
  • HY-100818
    Futibatinib
    2 Publications Verification

    TAS-120

    		 FGFR Cancer
    Futibatinib (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. Futibatinib inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9 nM; V5651=1-3 nM; N550H=3.6 nM; E566G=2.4 nM) .
    Futibatinib

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: